TICKERNERD
Menu
FBIOFBIOHealthcare · Biotechnology

FBIO Stock Forecast: Fortress Biotech, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.52
−1.95% on the day

The 2 Wall Street analysts covering Fortress Biotech, Inc. hold a median 12-month price target of $11 — +336.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 11 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$84.0M
Ticker Nerd rank
78 / 100
Median analyst target
$11
Analysts covering
2
Revenue$18.7M+14.0% y/y
Operating income−$10.0M
Net income$602K
Free cash flow−$59.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.0%
1M
−3.4%
YTD
−31.1%
1Y
−34.2%
From 52W high
−42.5%
From 52W low
+13.5%
$2.22
$4.38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fortress Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Growth
92
Size
77
Volatility
68
Issuance
62
Revisions
56
Momentum
49
Accruals
42
Value
28

Quality (94): The business earns solid, repeatable profits on what it owns.

Value (28): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26FBIOHigh $17Median $11Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $5Median $11High $17

The green dot is the last close — the median target sits +336.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
23 Feb 2026HC Wainwright & Co.ReiteratesBuy$17
21 Aug 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025Roth MKMReiteratesBuy—
18 Nov 2024HC Wainwright & Co.MaintainsBuy—
19 July 2024HC Wainwright & Co.ReiteratesBuy—
20 June 2024Cantor FitzgeraldReiteratesOverweight—
16 May 2024Roth MKMReiteratesBuy—
19 Mar 2024Alliance Global PartnersInitiatesBuy—
15 Mar 2024Roth MKMReinstatesBuy$10
29 Nov 2023Roth MKMMaintainsBuy—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight$5.00
16 May 2023Cantor FitzgeraldMaintainsOverweight$6.00 → $5.00
6 Apr 2023BenchmarkReiteratesSpeculative Buy$5.00
4 Aug 2022Ladenburg ThalmannInitiatesBuy$6.00
14 July 2022B. Riley SecuritiesMaintainsBuy$8.00 → $6.00
20 Apr 2021Roth CapitalMaintainsBuy$4.50 → $5.00
13 Oct 2020Roth CapitalMaintainsBuy$5.00 → $4.75
12 Oct 2020HC Wainwright & Co.MaintainsBuy$11 → $10
2 Oct 2020BenchmarkInitiatesBuy—
13 Mar 2020B. Riley FBRMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Fortress Biotech, Inc. returned −34.2% against +17.5% for the S&P 500, dividends included.

FBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26FBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Fortress Biotech, Inc. (FBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.9×

Cheaper than 71% of US stocks

Price / sales
1.2×

Cheaper than 65% of US stocks

Price / book
0.5×

Cheaper than 85% of US stocks

EV / EBITDA
0.6×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
14.0%

Higher than 61% of US stocks

Earnings growth (YoY)
14.0%

Higher than 52% of US stocks

Gross margin
67.2%

Higher than 80% of US stocks

Operating margin
−53.5%

Higher than 16% of US stocks

Net margin
163.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
116.0%

Higher than 97% of US stocks

Return on assets
−7.8%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fortress Biotech, Inc. (FBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fortress Biotech, Inc. has a market value of $84.0M and an enterprise value of −$15.6M.

  • Revenue in the twelve months to 30 June 2026: $68.5M. The latest quarter grew 14.0% year on year.

  • Net income over the same four quarters: $141.2M, a 206.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $125.8M.

  • Fortress Biotech, Inc. spent $14.3M on share buybacks and $473K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 33.3M.

  • Trailing P/E: 0.9×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Fortress Biotech, Inc. employs 78 people — $878K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

FBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBIOFortress Biotech, Inc.$84.0M
78
PTHSPelthos Therapeutics, Inc.$83.8M
20
VRCAVerrica Pharmaceuticals, Inc.$84.3M
73
NTRBNutriband, Inc.$84.6M
34
ACRVAcrivon Therapeutics, Inc.$85.6M
67
ALDXAldeyra Therapeutics, Inc.$80.8M
50
TELOTelomir Pharmaceuticals, Inc.$80.5M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fortress Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FBIO news & analysis

Journey Medical Corporation to Participate in September 2026 Investor Conferences

GlobeNewsWire · 8 Sept 2026neutral

Journey Medical Corporation announced that its Co-Founder, President and CEO Claude Maraoui will participate in two investor conferences in September 2026. The company develops and markets FDA-approved prescription products for dermatological conditions.

Why it matters — For Fortress Biotech watchers, Journey Medical is a related portfolio company, so its investor conference participation signals ongoing shareholder and market engagement.

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Fortress Biotech announced that CEO Lindsay A. Rosenwald will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available for on-demand viewing by attendees starting September 11, 2026, and the company will participate in one-on-one meetings during the conference from September 14-16, 2026.

Why it matters — A Fortress Biotech watcher would care because the presentation offers investors an opportunity to hear directly from executive leadership about the company's corporate overview at a major industry investment conference.

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewsWire · 13 Aug 2026positive

Fortress Biotech reported second quarter 2026 financial results, with total net revenue rising 14% to $18.7 million compared to the same period in 2025. The company also highlighted advancements in its partnered programs, including Crystalys Therapeutics' $130 million Series B financing to support dotinurad development and royalties from the launches of ZYCUBO and UNLOXCYT.

Why it matters — The 14% revenue increase, Series B financing for a partnered program, and new product royalties signal progress across Fortress's revenue and partnered-program activities in the latest quarter.

Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

A transcript of Fortress Biotech, Inc.'s Q2 2026 earnings call was published on Seeking Alpha, based on the company's second-quarter 2026 earnings conference. The item provides a record of the company's earnings call discussion.

Why it matters — FBIO watchers would care because the earnings call transcript offers insight into management's commentary on the company's latest quarterly results.

Fortress Biotech Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

On its second-quarter earnings call, Fortress Biotech highlighted that subsidiary Journey Medical reported higher revenue and improved profitability, driven by continued prescription growth and better payer reimbursement for its rosacea treatment Emrosi.

Why it matters — For Fortress Biotech watchers, Journey Medical's stronger performance signals improving commercial traction for a key subsidiary's lead product.

FAQ

Frequently asked questions about FBIO stock

What is the FBIO stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Fortress Biotech, Inc. have a median 12-month price target of $11, with estimates ranging from $5 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBIO stock a buy right now?

Of the 2 analysts covering Fortress Biotech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fortress Biotech, Inc. 78 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBIO?

As at 11 Sept 2026, Fortress Biotech, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will FBIO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +336.5% from the last close, and Ticker Nerd's factor model ranks Fortress Biotech, Inc. 78 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBIO stock forecast for 2030?

No analyst covering Fortress Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $17 over the next 12 months.

How has FBIO stock performed over the past year?

Fortress Biotech, Inc. returned -34.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fortress Biotech, Inc. do?

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biotechnology products.

What is the latest news on FBIO?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Journey Medical Corporation to Participate in September 2026 Investor Conferences". Journey Medical Corporation announced that its Co-Founder, President and CEO Claude Maraoui will participate in two investor conferences in September 2026. The company develops and markets FDA-approved prescription products for dermatological conditions.

Company

About Fortress Biotech, Inc.

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biotechnology products. Fortress Biotech operates through two core areas: dermatology product sales and pharmaceutical and biotechnology product development. Its commercial portfolio includes prescription and specialty dermatology therapies used for conditions such as acne, rosacea, hyperhidrosis, and other skin-related disorders, alongside wound-care and supportive treatment products. The company also advances a broader pipeline and portfolio of assets through its subsidiary and partner network, supporting programs in areas such as rare diseases and oncology. Fortress Biotech plays a role in the healthcare market by combining product sales with asset development, royalties, and other collaboration-based revenue streams. Headquartered in Bay Harbor Islands, Florida, Fortress Biotech serves a range of medical professionals and patients across the United States and international markets.

CEO Dr. Lindsay Allan Rosenwald M.D. · 78 employees · United States · https://www.fortressbiotech.com